Background: Understanding fate choice and fate switching between the osteoblast lineage (ObL) and adipocyte lineage (AdL) is important to understand both the developmental inter-relationships between osteoblasts and adipocytes and the impact of changes in fate allocation between the two lineages in normal aging and certain diseases. The goal of this study was to determine when during lineage progression ObL cells are susceptible to an AdL fate switch by activation of endogenous peroxisome proliferator-activated receptor (PPAR)c.
Introduction
Multipotent mesenchymal stem cells differentiate into osteoblasts, adipocytes and other mesenchymal lineages, and key transcription factors underlie commitment and fate choices of cells to particular lineages with suppression of alternative lineages [1, 2, 3] . Considerable evidence supports the notion that osteoblasts and adipocytes are closely related through a common progenitor. For example, a decrease in bone volume in age-related and steroid-induced osteoporosis is accompanied by an increase in marrow adipose tissue (see for example, [4, 5] ). A variety of experimental manipulations in primary bone marrow stromal cells and cell lines have contributed molecular and cellular insight into the mechanisms underlying the apparent reciprocal relationship between the two lineages (see for example, [1, 6, 7, 8, 9, 10, 11] ). These studies have led to the suggestion that regulated lineage allocation of stem or multipotential progenitor cells or a fate switch from osteoblast lineage (ObL) to adipocyte lineage (AdL) occurs under certain conditions, including aging. However, it is unclear at what commitment or differentiation stage(s) fate changes occur.
Peroxisome-proliferator activated receptor (PPAR)c, a ligandactivated transcription factor belonging to the nuclear hormone receptor superfamily, is expressed principally in adipose tissue and heterodimerizes with a retinoid X receptor to bind the PPAR response elements within the promoters of target genes, including adipocyte-associated genes. Thus, PPARc (PPARc2, in particular) acts as a master regulator of the adipocyte developmental program together with other transcription factors, such as PPARa and CCAAT enhancer-binding proteins (C/EBPs) [12, 13, 14] . Thiazolidinediones, anti-diabetic agents including rosiglitazone (BRL-49653 (BRL)), are frequently used synthetic ligands for PPARc [15] and stimulate adipogenesis and inhibits osteoblastogenesis in vivo and in vitro [8, 9, 10, 11] . This may be implicated in downregulation of runt-related transcription factor 2 (Runx2) in a bone marrow-derived cell line overexpressing PPARc2 [16] .
Evidence from PPARc haploinsufficient mice also supports the concept that PPARc is antagonistic to osteogenesis, acting early in mesenchymal cell differentiation [1] . In contrast, microarray analysis of mesenchymal lineage markers in mouse calvaria cell cultures indicates that adipocyte-(except PPARc) but not myocyte-asssociated genes are transcriptionally induced together with osteoblast-associate genes during osteoblast development [17] . Similarly, our recent data show that adipocytes emerge along with osteogenic potential in a fraction of fetal rat calvaria cells treated with BRL [18] . Developmental regulation of calvaria cells, a frequently used model of ObL cells, is different in at least certain respects, from that of marrow stromal cells, suggesting that these diverse results may reflect differences in PPARc regulation of osteo-adipogenic fate choice in the two organs. However, dissecting when during ObL lineage progression cells may be susceptible to fate switches is complicated by the fact that although osteoblast differentiation is well characterized [19] , phenotypic heterogeneity of ObL cells is seen in multiple cell culture models, including stromal and calvarial cells, as well as in developing rat calvariae [20] . This heterogeneity includes cellular responses to cytokines and hormones (e.g., parathyroid hormone (PTH)/PTH related protein receptor in cortical versus trabecular bone compartments [21] ).
Based on all of these data, we hypothesized that subsets of ObL cells may differentially respond to PPARc. By preparing ObL cells at multiple differentiation stages from rat calvariae either by magnetic cell sorting using anti-alkaline phosphatase (ALP, a marker of relatively early ObL progression) antibody or by replica plating of single cell-derived colonies, we identified and characterized a distinct subset of ObL cells that can convert into adipocytes in the presence of BRL.
Results

Multiple cellular pathways lead to adipogenesis in ObL cells
As described previously [18] , ObL cells from fetal rat calvariae proliferated (day 0-5), reached confluence and subsequently formed cell condensations (day 5-6), followed by nodule formation (differentiation, day 6-10) (Fig. S1 ) and mineralization (maturation, not shown). This developmental process was also confirmed by gene expression profiling of osteoblast markers (Fig. S2A) . ObL cells chronically treated with BRL were morphologically similar to those without BRL up to day 5-6, and thereafter adipocytes were seen within cell condensations (Fig. S1 ). In contrast to what was seen in BRL-treated cultures, a very few adipocytes were dispersed in control cultures without BRL, but they disappeared as ObL progression occurred (data not shown). Likewise, colony formation assays revealed that there were only a few colony-forming unit (CFU)-adipocyte colonies without BRL (Fig. 1A) . BRL, however, increased not only CFU-adipocyte (Fig. 1A) but also CFU-ALP colonies (Fig. 1B,C) . When we treated cells in which mineralized nodules had already formed with BRL for 5 days, a few adipocytes were present within some of the mineralized nodules (Fig. 1D) , raising the possibility that adipocytes may arise even from relatively mature ObL cells. To separate mature ObL cells from multipotential progenitors (e.g., side population cells [22] ), and other potentially contaminating lineages present in the primary cell digestion, we next released cells by enzymatic digestion from nodule-forming cells (day 10), and separated them into ALPpositive (ALP + ) and ALP-negative (ALP 2 ) fractions [23] by magnetic cell sorting (Fig. 1E ). Adipocytes formed diffusely (Fig. 1F ) in all fractions treated with BRL, although the number of adipocytes present varied with ALP 2 .control/unfractionated.ALP + (Fig. 1G ). To define whether adipogenic potential is restricted to a specific subset of ObL cells, we used a combination of single cell colony assays and replica plating [24, 25] . ObL colonies were retrospectively identified by ALP/von Kossa staining of their corresponding replicas (Fig. 1H) . Cells in individual colonies displayed homogenous morphology (Fig. 1I) and ALP activity, i.e., colonies comprised ,100% ALP 2 or ALP + cells (Fig. 1J ). Over 160 colonies from 12, 15, 17, and 21 days of culture were collected in each of two independent experiments; a portion of cells of each colony was re-plated at high cell density with BRL, while the remainder was collected for total RNA preparation. One hundredfifteen and 132 colonies in each experiment were successfully adapted to subculture, and of these, 94 and 95 respectively were designated osteoblast lineages, as verified by replica dishes ( Fig. 1K ). Notably, colonies picked and subcultured at day 12 exhibited mainly monopotential adipogenic fate at subculture, while colonies picked on day 21 were mainly monopotential but for osteogenic fate. Double-positive colonies/ bipotential fate occurred mainly in colonies isolated at days 15, 17 and 21. Taken together, the results suggest that some ObL cells, including cells already partially differentiated/maturing, can adopt an adipo/osteogenic fate, but that mature osteoblasts have a much lower probability to do so, at least under the conditions tested.
Gene expression profiling of single cell-derived colonies and its relationship to osteo/adipogenic potential Table S1 ). Based on their osteoblast marker expression and the established osteoblast hierarchy [19] , colonies were rearranged into an order from early (immature) to late stages of ObL progression, i.e., immature (negative for all of ALP, bone sialoprotein (BSP) and osteocalcin (OCN)), intermediate (negative for either ALP, BSP, or OCN) or mature (positive for all osteoblast markers) colonies (Fig. 2) . It is important to note that all colonies listed were committed to the ObL, as evidenced by Runx2 gene expression and ALP/von Kossa staining outcomes in replica dishes as described above. About 20% of colonies in subcultures supplemented with BRL were double negative (Table 1 ) and had fibroblastic morphology (not shown). There was a clear developmental stage dependency in the frequency with which osteoadipogenic mono-or bipotential colonies occurred; analysis by expression profiling was similar to, but more robust than, what was detected by cytochemistry (Table S1 and Fig. 2 ). There were significant differences in PPARa and PPARc mRNA levels in colonies that gave rise to either ALP + or oil red O + and between ALP + /oil red O + and oil red O + colonies in BRL-treated matched subcultures (Table 2) . Further, PPARa mRNA levels in colonies monopotential for adipogenic fate (oil red O + ) were significantly higher than those in colonies defined as osteo-adipogenic bipotential ( Table 2 ). In contrast, C/EBPs expression levels and osteo-adipogenic activities were poorly or not correlated (Table 2) . Taken together, the data suggest that the adipogenic potential of ObL cells may be defined by the relative levels of PPARc and PPARa versus other marker mRNAs.
To confirm that adipogenic fate of ObL cells is defined by relative levels of PPARc and PPARa, we co-treated rat calvaria cells with BRL plus rabbit serum (RS), the latter known to stimulate PPARa gene expression [26] ; co-treatment resulted in an inverse relationship between the number of bone nodules (decrease) and adipocyte colonies (increase) that formed (Fig. 3A,B ) with no effect on total colony number (Fig. 3C ). Amongst PPAR and C/EBP family members, PPARa and C/ EBPd mRNA levels were increased by RS (Fig. 3D) . However, fenofibrate, a synthetic PPARa ligand [27] , combined with BRL, did not fully mimic the RS plus BRL effect (Fig. 3E,F) , suggesting that RS may elicit other activities, including induction of C/EBPd, to induce adipogenesis. In any case, our results indicate that committed ObL cells unambiguously defined by marker expression profile and functional endpoints exhibit diverse molecular phenotypes as characterized by expression of non-osteoblastic mesenchymal lineage markers. That the diversity extends beyond adipogenic regulatory genes was confirmed by profiling two transcription factors involved in myogenesis (MyoD) and chondrogenesis (Sox9); these were also expressed in 22 and 20% of osteogenic colonies in developmentally immature (stage 1) and intermediate (stage 2) stages respectively (one colony expressed both), but not in any colonies at mature stages (Fig. S3) . Individual ObL cells identical in osteoblast development stage are molecularly and functionally distinct By assessing single cell-derived colonies, we showed that rat calvaria cells comprise a heterogeneous mixture of ObL cells with different gene expression profiles and different potential for fate switching. However, as is well-established [19] , the rat calvaria cell population expresses a temporally reproducible sequence of osteoblast development (see description above and the sequential upregulation of oteopontin (OPN), ALP and OCN in Fig. S2A ). We therefore also assessed mRNA expression of mesenchymal lineage-commitment transcription factors, such as Runx2, PPARc, Sox9 and MyoD in this model (Fig. S2A) . In contrast to Runx2, which increased slightly during the differentiation time course, Sox9 and MyoD were highest early (day 3) and progressively decreased thereafter. Levels of PPARc1 and c2 peaked at day 6 and subsequently decreased. Western blot analysis confirmed that Runx2 and PPARc protein expression paralleled that of their mRNAs (Fig. S2B) .
Immunofluorescence staining of proliferating rat calvaria cells (day 3) with antibodies against the same transcription factors revealed that all were localized in the cytoplasm (Fig. 4A ). All four factors were also present in cells in nodules, however the number of cells with detectable expression of PPARc, Sox9 and MyoD in nodules was fewer than those expressing Runx2 (Fig. 4B) . In subcultures of more mature cells from nodules (see above, ALP + fractions), Runx2 was clearly located in the nucleus, but other Total, recovered from master dishes 51 (18) 34 (30) 42 (34) 41 (39) 55 (11) 39 (32) 38 (35) 40 (38) Total, subcultured successfully 26 (17) 29 (26) 34 (26) 28 (28) 33 (8) 31 (23) 30 (28) 38 (36) ALP positive 1 (1) 3 (3) 7 (7) 21 (21) 3 (2) 5 (5) 7 (7) 28 (28) Oil red O positive 16 (14) 3 (3) 2 (2) 0 (0) 11 (4) 3 (2) 6 (5) 0 (0) Double positive 2 (2) 14 (14) 11 (11) 3 (3) 1 (1) 14 (13) 10 (10) 2 (2) Double negatve 7 (0) 9 (6) 14 (6) 4 (4) 8 (1) 9 (3) 7 (6) factors remained cytoplasmic (Fig. 4C) . Western blotting of subcultures of the ALP + fraction revealed that the subcellular localization of Runx2 did not differ between cells treated or not with BRL for 12 h, whereas PPARc was primarily localized in the nucleus in the presence but not absence of BRL (Fig. 5A) . Consistent with this, some cells within the ALP + fraction and positive for nuclear Runx2 were also positive for nuclear PPARc but not for Sox9 (Fig. 5B) . In parallel cultures, BRL increased PPARc and adipsin, but did not alter mRNA levels of other transcription factors or OCN by 24 h post-induction (Fig. 5C-H) . These results suggest that some ObL cells express PPARc that remains in the cytoplasm, while others can mobilize PPARc to the nucleus; it is presumably these latter cells that convert into adipocytes under the stimulus of PPARc-specific ligands.
Discussion
A comprehensive in vitro analysis of the effects of BRL on osteoadipogenic potential in the ALP + fraction of rat calvaria cells and in retrospectively identified single cell-derived definitive ObL colonies from rat calvaria cells suggests that developmentallyregulated endogenous levels of PPARs contribute to the potential of ObL cells to convert to adipocytes in the presence of BRL. We also suggest that ObL cells are heterogeneous with respect to expression of non-osteoblastic phenotypic traits, and capacity for alternative fate choices with at least some maintaining capacity for fate switches even at relatively late osteoblast differentiation stages. Cells were plated at very low density as described in Fig. 1 As described [1, 6, 7, 8, 9, 11] , bone marrow cell models in vivo and in vitro including ours [18] , all support a model in which adipocytes form at the expense of osteoblasts, which may be processed at least in part by the PPARc-mediated downregulation of Runx2 [16, 28] . Only a few studies have addressed adipogenic potential in the calvaria cell model. Runx2-deficient calvaria cells show adipo-chondrogenic bipotentiality [29] , and the mouse calvaria-derived cell line MC3T3-E1 displays increased adipogenesis and decreased osteoblastogenesis with retroviral overexpression of PPARc [30] . However, because the cells in both these latter models had lost the typical osteoblastic features before analysis, it is difficult to define unambiguously which particular ObL cells undergo transdifferentiation into adipocytes. Sorting ObL cells based on expression of ALP, a well-established osteoblast marker, allows enrichment for immature versus more mature osteoblastic precursors [23] . Thus, BRL-dependent adipogenesis in the ALP + fraction of ObL cells suggests that not only immature but also maturing osteoblastic cells exhibit adipogenic potential. A combination of limiting dilution single colony assays and replica plating is a useful technique to trap cells at definable developmental stages [24, 25] . In spite of the possibility of a gradient in the proliferation-differentiation sequence from the periphery to the center of developing bone colonies [31] , the uniform ALP staining we saw in colonies selected here and the lack of a relationship between the colony size (not shown) and their developmental stage suggest that a development gradient, if present under our culture conditions, was restricted to a narrow range. Using this approach, we found a statistically significant difference in the adipogenic potential amongst colonies defined as being at three development stages: immature, intermediate and mature, but adipocytes were found in all three.
Ectopic overexpression of PPARc [30] or treatment with high doses of PPARc ligands [8, 9, 10, 11, 16] in several models elicits reciprocal up-and downregulation of adipogenesis and osteoblastogenesis, respectively. On the other hand, BRL at relatively low concentrations has no pro-adipogenic effect in MC3T3-E1 cells [32] . Because high concentrations of PPARc and/or their ligands may abrogate their specificity on downstream target genes [33] , we used BRL at a maximum concentration of 100 nM. Indeed, we found that BRL (#100 nM) does not induce adipocytes in MC3T3-E1 cells without PPARc overexpression (data not shown), in agreement with previous data [32] . We also showed previously a clear difference in the capacity of BRL to alter the fate choice of precursor cells in stromal (bone marrow) versus calvaria-derived cell populations [18] , and now characterize the distinct subset of ObL cells having adipogenic potential.
Fatty acid-rich RS increases PPARc and PPARa mRNA expression in various osteoblastic cell lines (MB1.8, ROS17/2.8 and SaOS-2/B10) with a resultant decrease in ALP activity and increase in adipocyte number [26] . Likewise, we found that RS in combination with BRL mimicked the reciprocal effect of BRL on osteogenesis versus adipogenesis in bone marrow cells. However, the effect appears not to be mediated solely by PPARa and c, because the PPARa activator fenofibrate was unable to substitute completely for RS. It is also worth noting that different PPARc ligands have differential effects on osteo-adipogenesis in vitro and in vivo and that the adipogenic and anti-osteogenic processes can be regulated independently [9, 34, 35] . For example, additional factors such as the basic-leucine zipper class of transcription factors, C/EBPa, b and d, are known to participate in adipogenesis [14] . Ectopic co-overexpression of C/EBPa and PPARc induces adipogenesis in the G8 myoblast cell line [36] as well as in MC3T3-E1 cells [30] . Although it was fairly widely expressed in diverse colony types, we did not find a significant correlation between levels of C/EBPa and adipogenic potential in the single cell-derived colony assay. Results with viral-mediated dual expression of C/EBPa and bone morphogenetic protein (BMP)2 in C2C12 myoblasts suggest that C/EBPa may bias BMP2-induced osteoblasts towards adipogenesis [37] . In contrast, it is known that C/EBPb/d and Runx2 interact to enhance OCN transcription [38] . Taken together, the data indicate that these multiple transcription factors act together within carefully regulated levels to determine osteo-adipogenic lineage progression.
PPARs and their downstream targets (e.g., adipsin, [39] ) are expressed during osteoblast development in our rat calvaria ObL model as well as two other independent in vitro osteoblastic models [17, 26] . However, mouse calvaria cells were reported to be more developmentally restricted than those multipotential mesenchymal cells expressing myoblast markers in addition to osteogenic or adipogenic markers, and were reported not to express PPARc during osteogenic differentiation [17] . While our data are in general agreement, with detectable expression of several mesenchymal lineage determinants in rat calvaria ObL cells, we also detected PPARc at both RNA and protein levels. However, our data suggest that the majority of the PPARc, as well as Sox9 and MyoD, are transcriptionally inactive and have no functional consequences since they are abundant in the cytoplasm but not the nucleus throughout osteoblast differentiation. It is known that the PPARc natural ligand 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) induces nuclear translocation of PPARc in mouse bone marrow stromal cells, whereas the reagent inhibits nuclear binding of Runx2 to DNA in the MC3T3-E1 and ST2 cells, in association with its adipogenic and anti-osteogenic activities [40] . Although the dynamics of nucleocytoplasmic shuttling of PPARc in the presence of BRL are poorly understood, we found that BRL promoted the nuclear translocation of PPARc in only a discrete subset of ObL cells and, indeed, Runx2/PPARc-double nuclearpositive cells were occasionally observed. Likewise, Sox9, when activated, over-rides Runx2 function in ObL cells as shown by the phenotypes seen in transgenic mice in which Sox9 is driven by the type Ia collagen promoter [41] . Thus, activation of PPARc (mostly c2; see also below) may over-ride Runx2 function in collaboration with other adipogenic transcription factors, such as PPARa and C/EBPs under specific conditions, resulting in conversion of particular ObL cells into adipocytes, as shown here.
PPARc has two major isoforms (c1 and c2), resulting from different promoter usage and alternative splicing. PPARc2 is restricted predominantly to adipose tissue where it is crucial for adipogenesis, but the adipogenesis seen in PPARc splice variantnull fibroblast cell lines suggests functional similarity between the isoforms [42] . Both PPARc1 and c2 are expressed in primary osteoblastic cells from human cancellous bone [43] , while the mouse MC3T3-E1 cell line does not express PPARc2 which led to the suggestion that PPARc1 positively regulates osteoblastogenesis in this model [32] . Consistent with this view, osteogenic differentiation is correlated with upregulation of PPARc1 (and the alternative transcripts c3 and c4) in two human osteoblast cell lines, SV-HFO and NHOST, and human mesenchymal stem cells [44] . Our observation that BRL enhanced nuclear translocation of PPARc in ObL cells and increased CFU-ALP colonies begs the question of why bone nodule formation is maintained despite increased adipogenesis in ObL cultures treated with BRL. Our data suggest that PPARc2 may have adipogenic and antiosteogenic potential, while PPARc1 may stimulate osteoblastogenesis, a possibility supported by results from microarray analysis of the mouse bone marrow cell line U-33 ectopically overexpressing PPARc. In this genetically-engineered line, rosiglitazone upand downregulates a large number of genes involved in multiple Figure 5 . BRL promotes PPARc actions in osteoblast-lineage cells. ALP + fractions isolated from developing RC cells (day10) were subcultured with or without 100 nM BRL as described in Fig. 1E-G. (A) BRL increases relative abundance of PPARc in the nucleus versus the cytoplasm. Cells at confluence were treated with or without 100 nM BRL for 12 h, and subcellular fractionation was performed. The nuclear and cytosolic fractions were subjected to Western blotting for PPARc and Runx2. (B) Double PPARc and Runx2 nuclear positive cells are present in cells cultured with BRL. After 2 days of plating, cells were treated with or without 100 nM BRL for 12 h, fixed and double stained with aRunx2 (green) and either aPPARc or aSox9 (red). (C) PPARc and adipsin mRNA levels are selectively increased by BRL. Cells at confluence were treated with or without 100 nM BRL for 24 h. Total RNA was extracted, and qRT-PCR for genes tested was carried out as shown in Fig. 3D . doi:10.1371/journal.pone.0011782.g005 signaling pathways before the downregulation of the ObL determinants Runx2, Dlx5, Osterix [45] . Thus, PPARc may be able to modulate osteoblast differentiation both dependently and independently of its negative effect on ObL determinants, and at multiple developmental stages.
In summary, we report that ObL cells co-express Runx2 and either PPARc, Sox9, MyoD or a combination of regulatory factors for multiple mesenchymal lineages but while Runx2 translocates to the nucleus during osteogenic differentiation, the latter do not, rendering them inactive under osteogenic differentiation conditions. However, activation of PPARc by treatment with its synthetic ligand, BRL, promotes nuclear translocation of PPARc and induces an adipogenic fate switch in a discrete subset of ObL cells characterized by relatively high levels of endogenous PPARs. The molecular basis by which this subset of osteogenic cells acquires high endogenous expression of adipogenic transcription factors, whether regulated or occurring stochastically, remains to be determined.
Materials and Methods
Ethics Statement
Animal use and procedures were approved by the Institutional Animal Care and Use Committee at the Central Institute for Experimental Animals and the Committee of Animal Experimentation at Hiroshima University (#A09-36) and by the University of Toronto Animal Care Committee (#20008196).
ObL cell culture
Cells were isolated from 21-day-old fetal Wistar rat calvariae by sequential collagenase (Type I; Sigma-Aldrich) digestion as described [46] . Cells from the last four fractions were separately grown in aMEM supplemented with 10% fetal bovine serum (Biological Industries) and antibiotics for 24 h. The cells were then trypsinized, pooled and grown at 0.35610 4 cells/cm 2 in the same medium supplemented additionally with 50 mg/ml ascorbic acid (osteogenic medium). In particular experiments, cells were treated with or without BRL (#100 nM) either in combination with or without RS (#2.5%) or in combination with fenofibrate (#100 nM), a synthetic ligand for PPARa.
CFU assay
Cells were plated at 150 cells per well in 96-well plates in osteogenic medium with or without 1-100 nM BRL for 10 days and double-stained with the diazo method (CFU-ALP) and oil red O (CFU-adipocyte) (see below).
Replica plating of single cell-derived colonies
Cells were plated at limiting dilution (#15 cells/cm 2 in 100-mm dishes) in osteogenic medium plus 10 nM dexamethosone (Dex), a stimulator of osteoblast differentiation in this model [47] . A few days later, polyester cloths (1 mm pore size) were placed over developing colonies for 24 h, then transferred upside down into new dishes with fresh osteogenic medium plus 10 nM Dex and 10 mM b-glycerophosphate (bGP) (replica dishes) [18, 24, 25] . Replica dishes were terminated at day 25 and subjected to ALP/ von Kossa staining (see below). On days 12, 15, 17, and 21, colonies in master dishes were gently scraped from the dishes by using forceps and digested with trypsin and collagenase. The resulting cell suspension from each colony was split in half; one half was subjected to total RNA extraction and the other half was subcultured (,2610 4 /cm 2 ) in osteogenic medium with 100 nM BRL. All cultures were maintained at 37uC in a humidified atmosphere with 5% CO 2 and medium was changed every second or third day.
Magnetic cell sorting
Differentiating cells in osteoid-like nodules (,day10 of culture) were digested with collagenase and trypsin, and the resultant cell suspension was incubated with biotinylated anti-ALP antibody (40 ml/5610 6 cells; R&D systems, Minneapolis, MN) for 20 min at 4uC. After washing, the cells were labeled with anti-biotin magnetic microbeads (5 ml/5610 6 cells; Miltenyi Biotec) for 20 minutes at 4uC and applied onto a magnetic column (Miltenyi Biotec). After collection of the ALP pass-through fraction (ALP 2 ), the column was removed from the magnetic field and the ALP ) was replated and incubated in osteogenic medium with or without 100 nM BRL; the remainder of each fraction was used to measure ALP activity.
ALP activity
Cells were washed with PBS and lysed by freeze-thawing (two times) in 0.05% TritonX 100. After centrifugation, ALP activity in cell lysates was measured with a LabAssay TM ALP assay kit (Wako Chemical) according to the manufacturer's instructions.
ALP/von Kossa/oil red O staining
Cells were rinsed with PBS and fixed in 10% neutral buffered formalin. For ALP staining, the cells were incubated with naphthol AS MX/red violet or blue in 0.1M Tris-HCl (pH 8.3) as described elsewhere [46] . Matrix mineralization was confirmed by further incubation with 2.5% silver nitrate solution. For adipocytes, fixed or ALP-stained cells were air-dried and incubated in oil red O [48] .
RT-PCR
Total RNA was isolated from cells with TRIzol reagent (Invitrogen). Two micrograms of total RNA was reversetranscribed by ReverTra Ace (Toyobo) at 50uC for 40 min. The sequence of primer sets for rat C/EBPa and d [49, 50] , OPN, ALP, BSP, OCN, and ribosomal protein L32 (internal control) were described elsewhere [47] ; rat Runx2, PPARc (directed to sequences in the 39 end of the common region of c1 and c2), PPARc1, PPARc2, PPARa, MyoD, Sox9, lipoprotein lipase (LPL) and adipsin were designed using Primer Picking (primer 3) (Table  S2 ). qRT-PCR was carried out according to the manufacturer's instructions (LightCycler; Roche Diagnostics) by using a SYBR Green 1 kit.
Adaptor ligation-mediated PCR
To determine gene expression in single cell-derived colonies with limited cell number, high-fidelity global mRNA amplification was performed (TALPAT, T7 RNA polymerase promoterattached, adaptor ligation-mediated, and PCR amplification followed by in vitro T7-transcription) [51] . Amplified cRNA was then reverse-transcribed, and qPCR was performed as above.
Immunofluoroscence microscopy
Cells on coverslips were washed with PBS, fixed with ice-cold acetone and air-dried. Cells were then pretreated with Dako R Protein Block at room temperature (RT) for 1 h, followed by incubation with primary antibodies (Runx2, PPARc, Sox9, and MyoD; 1:50; Santa Cruz Biotechnology) at 4uC overnight. Cy TM 3-and/or Cy TM 2-conjugated secondary antibodies (1:400; Jackson Immunoresearch Laboratories) were used at RT for 1 h. Each incubation step was followed by two washes with PBS (5 minutes each). As negative control, normal goat or rabbit IgG (Vector) replaced primary antibodies.
Western blotting
Cells were lysed with 100 mM KCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonylfluoride and complete protease inhibitor (Roche Diagnostics) in 50 mM Tris-HCl (pH 7.5). Subcellular fractionation was carried out with a Qproteome Cell Compartment kit (Qiagen). Aliquots of samples were subjected to SDS-PAGE on 10-15% gels under reducing conditions and electroblotted onto nitrocellulose membranes. The membranes were treated with primary antibodies as above (1:500) at 4uC overnight. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (1:2,000, Santa Cruz Biotechnology), followed by chemiluminescence detection. Anti-b-actin antibody (1:1,000, Santa Cruz Biotechnology) was used as control.
Statistical Analysis
Unless otherwise specified, data from triplicate samples are expressed as the mean 6 SD, and a minimum of two independent experiments were performed. Statistical differences were evaluated by analysis of variance (ANOVA) and post hoc Student's t-test. Figure S1 Morphological changes in RC cell population cultures in osteogenic medium with or without BRL. Cells were chronically treated with or without 100 nM BRL. Phase-contrast microscopy shows images at multiple development stages. Upper panels, because there is no morphological difference between cells with and without BRL until cell condensation, typical images of cells at day 3 (d3) and d6 in the presence of BRL are shown. Middle and bottom panels, cells at d8 and d10, respectively, in the presence (+) and absence (2) 
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